US Pharma MarketingNovartis and Takeda drugs gain rare blood cancer routine use on NHS
Novartis and Takeda drugs gain rare blood cancer routine use on NHS is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The therapies’ availability will offer a route to personalised, mutation-specific approaches for types of rare blood cancers.
Source: Pharmaceutical Technology